Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jubbonti is a prescription RANK ligand inhibitor containing denosumab-bbdz. It is biosimilar to Prolia. Current labeling includes osteoporosis treatment, glucocorticoid-induced osteoporosis, and selected bone loss associated with androgen deprivation therapy or aromatase inhibitor therapy.
read more about jubbonti ...Denosumab-bbdz binds to RANK ligand and prevents it from activating RANK on osteoclasts and their precursor cells. This inhibits osteoclast formation, function, and survival, reducing bone resorption and increasing bone mass and strength.
Jubbonti is used in postmenopausal women with osteoporosis at high fracture risk, men with osteoporosis at high fracture risk, and adults with glucocorticoid-induced osteoporosis at high fracture risk. It also increases bone mass in selected men receiving androgen deprivation therapy for nonmetastatic prostate cancer and selected women receiving adjuvant aromatase inhibitor therapy for breast cancer.
The recommended dose is 60 mg by subcutaneous injection once every six months in the upper arm, upper thigh, or abdomen. A healthcare professional administers the injection. Patients receive calcium 1000 mg daily and at least 400 IU of vitamin D daily during treatment.
Jubbonti carries a boxed warning for severe hypocalcemia in patients with advanced kidney disease, including dialysis-dependent patients. Other serious concerns include osteonecrosis of the jaw, atypical femoral fractures, multiple vertebral fractures after discontinuation, serious infections, severe skin reactions, and fetal harm. Pre-existing hypocalcemia is corrected before treatment.
Jubbonti is a denosumab-bbdz product that inhibits RANK ligand and is biosimilar to Prolia.
The recommended dose is 60 mg by subcutaneous injection once every six months.
Yes. Current labeling calls for calcium 1000 mg daily and at least 400 IU of vitamin D daily.
Yes. The boxed warning concerns severe hypocalcemia in patients with advanced kidney disease.
Denosumab Injection: MedlinePlus Drug Information. https://www.medlineplus.gov/druginfo/meds/a610023.html. Date Accessed October 6, 2026.
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. https://pubmed.ncbi.nlm.nih.gov/27270237/. Date Accessed October 6, 2026.
Denosumab-bbdz: A Review of the Interchangeable Biosimilar for the Treatment of Osteoporosis. https://pubmed.ncbi.nlm.nih.gov/40509651/. Date Accessed October 6, 2026.
FDA Approves First Interchangeable Biosimilars to Prolia and Xgeva to Treat Certain Types of Osteoporosis and Prevent Bone Events in Cancer. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-prolia-and-xgeva-treat-certain-types-osteoporosis-and. Date Accessed October 6, 2026.
JUBBONTI (Denosumab-bbdz) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bf239bb-c467-4add-b7cf-ea666e4fc693. Date Accessed October 6, 2026.